Group 1 - The core point of the article is the successful selection of Hunan Warner Pharmaceutical Co., Ltd.'s Benidipine Hydrochloride Tablets in the 11th batch of national centralized drug procurement, highlighting the company's competitive edge in the pharmaceutical market [1][2] - The centralized procurement included 55 types of commonly used drugs across various therapeutic areas, with participation from 4.6 million medical institutions and 445 companies submitting bids [1] - Benidipine Hydrochloride Tablets are a long-acting third-generation dihydropyridine calcium antagonist used for treating primary hypertension and angina, addressing a significant health concern in China where cardiovascular diseases affect 330 million people [2] Group 2 - The national procurement emphasizes "stabilizing clinical use and ensuring quality," raising the quality control standards for participating companies [3] - Warner Pharmaceutical has maintained a 100% pass rate in national quality inspections for its procurement products, establishing a strong quality brand [3] - The company has actively embraced centralized procurement policies, with 22 products selected in national or regional procurements, demonstrating its adaptability to policy changes [3]

Core Insights - Warner Pharmaceutical (688799.SH) reported a revenue of approximately 1.086 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.55% [1] - The net profit attributable to shareholders for the same period was about 207 million yuan, showing a significant year-on-year increase of 30.75% [1] Revenue Composition - The revenue composition for the first three quarters of 2025 includes approximately 805 million yuan from formulation products, 262 million yuan from active pharmaceutical ingredients (APIs) and intermediates, and 12 million yuan from technical services [1] Company Development - After over 20 years of development, Warner Pharmaceutical has become a key member of the Hunan biopharmaceutical industry chain, with 71 specialty chemical API varieties and 59 chemical drug formulation registration certificates [1] - The company has transitioned the registration status of 53 APIs to "A" and possesses the capability to supply dozens of intermediates and over 20 pharmaceutical excipients [1] R&D Investment - Warner Pharmaceutical continues to increase its investment in research and development, with R&D expenditures of 106 million yuan in the first three quarters of this year, accounting for 9.75% of its operating revenue [1] Innovation and Drug Development - In addition to generic drug development, Warner Pharmaceutical is advancing multiple innovative drugs, including the traditional Chinese medicine Qianqing Granules, which has entered Phase III clinical trials [2] - The company is also progressing with the ZY series of endangered animal material substitutes through its subsidiary Tianji Zhenxi, in line with clear regulatory guidelines [2] Strategic Focus - The company aims to solidify its foundation through concentrated efforts on generic drugs while fostering potential breakthroughs in innovative drugs, adhering to a "combination of generic and innovative" development strategy [2]

Core Points - The Shanghai Composite Index closed at 3961.62 points, above the six-month moving average, with a decline of 0.63% [1] - The total trading volume of A-shares reached 157.92 billion yuan [1] - A total of 259 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3961.62 points, indicating a slight decline of 0.63% [1] - The total trading volume for A-shares today is reported at 157.91 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 259 A-shares have broken through the six-month moving average, with the highest deviation rates observed in stocks such as: - Yatong Precision Engineering (8.20%) - Excellent New Energy (7.57%) - Deyuan Pharmaceutical (7.38%) [1] - Other stocks with smaller deviation rates include: - New Hope - Shanghai Phoenix - Angli Education, which have just crossed the six-month line [1] Notable Stocks and Their Metrics - Top stocks with significant price changes and their metrics include: - Yatong Precision Engineering: +9.76%, turnover rate 31.45%, six-month line 23.27 yuan, latest price 25.18 yuan, deviation rate 8.20% [1] - Excellent New Energy: +9.90%, turnover rate 2.44%, six-month line 45.62 yuan, latest price 49.07 yuan, deviation rate 7.57% [1] - Deyuan Pharmaceutical: +11.83%, turnover rate 8.02%, six-month line 38.03 yuan, latest price 40.84 yuan, deviation rate 7.38% [1]

Group 1 - Warner Pharmaceuticals (688799.SH) reported its Q3 2025 results on October 31, 2025, with 9 institutional investors disclosing holdings totaling 56.8213 million shares, representing 43.27% of the company's total equity [1] - The institutional ownership percentage decreased by 2.77 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 4 funds reduced their holdings compared to the previous quarter, with a total reduction of 0.50% [2] - One new public fund disclosed its holdings this quarter, namely the China Europe Enjoy Life Mixed Fund [2] - A total of 132 public funds did not disclose their holdings this quarter, including notable funds such as Invesco Great Wall Research Selected Stock A and China Europe Medical Health Mixed A [2]

Core Viewpoint - Warner Pharmaceuticals (688799) reported a mixed financial performance for the first three quarters of 2025, with a notable increase in net profit but a decline in non-recurring profit, alongside a temporary production halt due to safety issues at a subsidiary [3][6][14]. Trading Information Summary - On October 30, 2025, Warner Pharmaceuticals closed at 49.49 yuan, down 1.2%, with a turnover rate of 1.56% and a trading volume of 20,500 shares, amounting to a total transaction value of 102 million yuan [1]. - The main funds saw a net outflow of 18.97 million yuan, accounting for 18.67% of the total transaction value, while retail investors had a net inflow of 6.35 million yuan, representing 6.25% of the total [2][6]. Financial Performance Summary - For the first three quarters of 2025, the company reported a main revenue of 1.086 billion yuan, a year-on-year increase of 1.54%, and a net profit attributable to shareholders of 207 million yuan, up 30.75% [3][7]. - In Q3 2025 alone, the main revenue was 372 million yuan, reflecting a 12.52% increase year-on-year, while the net profit attributable to shareholders surged by 198.16% to 136 million yuan [3][7]. - The company's debt ratio stood at 28.36%, with investment income of 87.36 million yuan and a financial expense of -776,690 yuan, resulting in a gross profit margin of 60.8% [3][7]. Company Announcements Summary - The Q3 report emphasized the accuracy and completeness of the financial information, with the board and management taking legal responsibility for the report's content [4]. - A subsidiary, Chiral Pharmaceuticals, was ordered to temporarily halt production due to safety violations, with plans to resume operations in early November after addressing the issues [14]. - The company has been actively involved in the national drug procurement process, with plans to expand its market presence through successful bids [13][14]. Shareholder Information Summary - As of the end of the reporting period, the total number of ordinary shareholders was 6,416, with the top ten shareholders holding significant stakes, including Hunan Warner Pharmaceutical Investment Partnership with 39.78% [10][11].

证券代码：688799 证券简称：华纳药厂 公告编号：2025-085 湖南华纳大药厂股份有限公司 关于增加暂时闲置自有资金现金管理额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召 开第四届董事会第一次会议和第四届监事会第一次会议，审议通过《关于使用部 分暂时闲置募集资金及自有资金进行现金管理的议案》，同意公司使用不超过人 民币 1.8 亿元（含 1.8 亿元）的暂时闲置募集资金，使用不超过人民币 3 亿元（含 3 亿元）的自有资金进行现金管理，用于购买安全性高、满足保本要求、流动性 好的现金管理产品，该决议有效期自公司董事会审议通过之日起 12 个月内，在 上述期限内可以滚动使用。具体内容详见公司于 2025 年 4 月 22 日在上海证券交 易所网站（www.sse.com.cn）披露的《湖南华纳大药厂股份有限公司关于使用部 分暂时闲置募集资金及自有资金进行现金管理的公告》（公告编号：2025-028）。 为进一步规范公司资金 ...

湖南华纳大药厂股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 7 日（星期五）15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 证券代码：688799 证券简称：华纳药厂 公告编号：2025-086 湖南华纳大药厂股份有限公司 关于召开2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 四、投资者参加方式 董事长、总经理：黄本东先生 董事会秘书：乔桥先生 财务负责人：吴桂英女士 独立董事：吴淳先生 如有特殊情况，参会人员可能进行调整 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 ...

公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688799 证券简称：华纳药厂 公告编号：2025-084 湖南华纳大药厂股份有限公司 第四届监事会第三次会议决议公告 表决结果：3 票同意，0 票反对，0 票弃权。 （二）审议通过《关于增加暂时闲置自有资金现金管理额度的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 一、监事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届监事会第三次会 议于 2025 年 10 月 30 日以现场结合通讯方式召开，本次会议的通知于 2025 年 10 月 20 日送达公司全体监事。会议由监事会主席马飞先生主持，应出席监事 3 人，实际出席监事 3 人。会议的召集、召开、表决程序符合相关法律、法规及《湖 南华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作 决议合法有效。 二、监事会会议审议情况 本次会议审议通过了如下议案： （一 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-083 湖南华纳大药厂股份有限公司 第四届董事会第三次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届董事会第三次会 议于 2025 年 10 月 30 日以现场结合通讯方式召开，本次会议的通知于 2025 年 10 月 20 日送达公司全体董事。会议由董事长黄本东先生主持，应出席董事 7 人， 实际出席董事 7 人。会议的召集、召开、表决程序符合相关法律、法规及《湖南 华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作决 议合法有效。 二、董事会会议审议情况 本次会议审议通过了如下议案： （一）审议通过《关于公司 2025 年第三季度报告的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 本议案已经第四届董事会审计委员会第三次会议审议通过。 表决结果：7 票同意，0 票反对，0 票弃权。 （二）审议通 ...

证券代码：688799 证券简称：华纳药厂 湖南华纳大药厂股份有限公司 2025 年第三季度报告 湖南华纳大药厂股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 372,112,446.65 | 12.52 ...